It is quite obvious that bone morbidity has a negative impact on our patients with breast cancer. The use of bone-modifying agents in this setting can yield significant quality-of-life benefits.
Aasems Jacob, MD
Advertisement
Articles by Aasems Jacob, MD
Advertisement
Latest Updated Articles
- Optimal Use of Bone-Targeted Agents in Breast Cancer
August 15th 2016
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD
2
How Might CAR T Cells and Bispecifics Evolve in Multiple Myeloma Therapy?
3
Moving Beyond R-CHOP: The Future of Upfront Precision Oncology in Lymphoma
4
Shifting Hematologic and Solid Tumor Units to Progressive Care Models
5